Among obese patients, apixaban was associated with a significantly lower risk of recurrent VTE, MB, and CRNM bleeding compared with warfarin
  Warfarin Apixaban   HR (95% CI) P value
No. of
events		 IR per 100
person-years		 No. of
events		 IR per 100
person-years
Recurrent VTE 638 7.3 317 5.6
 
 0.73 (0.64-0.84) <.001
Major bleeding 546 6.2 265 4.6
 
 0.73 (0.62-0.85) <.001
GI bleeding 308 3.5 155 2.7
 
 0.76 (0.61-0.93) .009
Intracranial bleeding 38 0.4 15 0.3
 
 0.61 (0.32-1.15) .126
Other major bleeding 216 2.4 103 1.8
 
 0.72 (0.56-0.92) .008
CRNM bleeding 2843 34.8 1579 29.2
 
 0.82 (0.77-0.88) <.001
GI CRNM bleeding 754 8.7 479 8.5
 
 0.95 (0.85-1.08) .441
Other CRNM bleeding 2185 26.2 1147 20.9
 
 0.78 (0.72-0.84) <.001
0.2
0.4
0.6
0.8
1
1.2
Favors apixaban
Favors warfarin
1|2|3